2,4,6-TMPEA-NBOMe

2,4,6-TMPEA-NBOMe
Clinical data
Other names	ψ-2C-O-NBOMe; 26O-NBOMe; NBOMe-TMPEA-6; N-(2-Methoxybenzyl)-2,4,6-trimethoxyphenethylamine
Routes of; administration	Oral, intranasal
Drug class	Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code	None;
Identifiers
	IUPAC name N-[(2-methoxyphenyl)methyl]-2-(2,4,6-trimethoxyphenyl)ethan-1-amine;
Chemical and physical data
Formula	C19H25NO4
Molar mass	331.412 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1cc(OC)c(c(c1)OC)CCNCc1ccccc1OC;
	InChI InChI=1S/C19H25NO4/c1-21-15-11-18(23-3)16(19(12-15)24-4)9-10-20-13-14-7-5-6-8-17(14)22-2/h5-8,11-12,20H,9-10,13H2,1-4H3; Key:NTLHTSWPAAMHIC-UHFFFAOYSA-N;

2,4,6-TMPEA-NBOMe, also known as ψ-2C-O-NBOMe or 26O-NBOMe as well as N-(2-methoxybenzyl)-2,4,6-trimethoxyphenethylamine, is a psychedelic drug of the phenethylamine, ψ-PEA, and N-benzylphenethylamine (NBOMe) families. It is the NBOMe derivative of ψ-2C-O (2,4,6-TMPEA). The drug is said to produce psychedelic effects such as visuals. It has been found to act as a potent serotonin 5-HT_2A receptor partial agonist, with an EC₅₀Tooltip half-maximal effective concentration of 1.7 nM and an E_maxTooltip maximal efficacy of 49%. 2,4,6-TMPEA-NBOMe was first described in the scientific literature in 2009. Subsequently, it was encountered as a novel designer drug in Russia in 2015. The drug is a controlled substance in Canada under phenethylamine blanket-ban language.